Webinar: What Does It Take to Get Digital Biomarkers Right in Clinical Trials?

Clinical trials are entering a new phase of data-driven innovation

With digital biomarkers, data from smartphones, wearables and sensors can help capture a more continuous and objective picture of a patient’s health in daily life, including measures such as movement, sleep and other behavioural or physiological signals.

In this webinar, NNIT and industry experts from Novartis and Boehringer Ingelheim will explore how digital biomarkers can move from promising innovation to practical clinical trial reality. The discussion will cover how high-quality data, emerging technologies and AI-enabled approaches can support better endpoint selection, improve patient relevance and help integrate digital measures into clinical workflows.

Join us to hear how pharma companies, technology partners, clinical sites and patients can collaborate across the digital health ecosystem to accelerate innovation, improve trial efficiency and unlock the value of data and AI in clinical research.

Agenda

1.  Proving Strategic Value and Selecting the Right Measure:

How do we demonstrate the essential value of digital biomarkers in drug development, ensure stakeholder alignment, and take the first step in selecting the right measure for the study?

2. Seamless Clinical Integration - From Patient Relevance to Regulatory Readiness:

What are the main barriers to adoption among patients and clinical sites, how do we ensure that digital biomarkers measure what matters, and how can we integrate, validate and qualify them efficiently across the relevant clinical development phase?

3. Implementation and Partnership:

Once the right measure is identified, what are the best practices for rolling it out, and how should pharma companies select the right technology partners? This includes the key choice between building internal innovation capabilities and partnering externally.

Who is speaking at the webinar?

• Stephane Wolf, Senior Global Executive, Boehringer Ingelheim

• Baris Ersezer, Digital Product Leader, Novartis

• Monika Zbytniewska-Megret, Senior Digital Biomarker Scientist, NNIT

Who is this session for? 

Whether you're in global pharma or an emerging biotech, this session is for anyone working with clinical trial data, endpoint strategy, or digital health innovation - from study operations to regulatory and technology partnership teams looking to move digital biomarkers from pilot to practice.